Skip to main content

Advertisement

SpringerLink
Log in

Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2

References

  1. Davies A, Jordanides NE, Giannoudis A, Lucas CM, Hatziieremia S, Harris RJ et al. Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia 2009; 23: 1999–2006.

    Article  CAS  PubMed  Google Scholar 

  2. White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006; 108: 697–704.

    Article  CAS  PubMed  Google Scholar 

  3. White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007; 110: 4064–4072.

    Article  CAS  PubMed  Google Scholar 

  4. White DL, Saunders VA, Quinn SR, Manley PW, Hughes TP . Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs. Blood 2007; 109: 3609–3610.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This research was supported by the Leukaemia Foundation of Australia. Special thanks to Novartis Pharmaceuticals for the provision of imatinib and nilotinib.

Author information

Authors and Affiliations

  1. Department of Haematology, SA Pathology, Adelaide, South Australia, Australia

    L Eadie, T P Hughes & D L White

  2. Department of Medicine, University of Adelaide, Adelaide, South Australia, Australia

    L Eadie, T P Hughes & D L White

  3. Centre for Cancer Biology, SA Pathology, Adelaide, South Australia, Australia,

    T P Hughes & D L White

Authors
  1. L Eadie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T P Hughes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D L White
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D L White.

Ethics declarations

Competing interests

Deborah White and Timothy Hughes receive honoraria and research funds from Novartis Pharmaceuticals, and are members of the Advisory Boards for Novartis. However, Novartis had no role in the design of the study, collection and analysis of data nor the decision to publish. Laura Eadie has no conflict of interest to disclose.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eadie, L., Hughes, T. & White, D. Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells. Leukemia 24, 855–857 (2010). https://doi.org/10.1038/leu.2010.7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2010.7

  • Springer Nature Limited

This article is cited by

Search

Navigation